Omar Nass is a Cardiology physician affiliated with Ford Motor Company. OpenAlex indexes 17 publications with 963 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7440 S 91st St
Lincoln, NE 685269797
Telephone
402-489-6555Provider last certified this registry record 22 Mar 2024.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year20254 payments
- PFIZER INC.Program year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.2%Beta blocker18.2%Carvedilol40%Metoprolol Succinate40%Metoprolol Tartrate6%Sotalol6%Bisoprolol Fumarate5%Nebivolol Hcl3%Part D<11 patientsStatin9.8%Atorvastatin Calcium72%Rosuvastatin Calcium28%Part D≥67 patients+ 13 more classes in this area
Blood & clotting
11.3%Factor Xa inhibitor8.1%Eliquis73%Xarelto27%Part D≥29 patientsVitamin K antagonist1.8%Warfarin Sodium100%Part D≥11 patients+ 1 more class in this area
Metabolism & gastrointestinal
9.5%Potassium supplement6.7%Potassium Chloride100%Part D≥44 patientsSGLT2 inhibitor2.8%Jardiance100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-term Pharmacological Activation of PPARγDoes not Prevent Left Ventricular Remodeling in Dogs with Advanced Heart Failure
Cardiovascular Drugs and Therapy
2007 - Effects of the AT<sub>1</sub>‐receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure
British Journal of Pharmacology
2003 - Effects of pre-existing left ventricular hypertrophy on ventricular dysfunction and remodeling following myocardial infarction in rats
The Journal of Heart and Lung Transplantation
2002 - Ranolazine, partial fatty acid oxidation inhibitor improves left ventricular function in dogs with heart failure
Journal of Molecular and Cellular Cardiology
2002
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”